Zacytuj

Fig. 1.

Gantt diagram depicting a timeline of patients’ admissions in relationship with the three wards and the length of stay in each ward. Epidemic curve based on the number of K. pneumoniae isolated in the time frame of the study.Abbreviations: OAIT-Department of Anaesthesia and Intensive Care, NR-Department of Neurology with the Stroke Subdepartment, REU-Department of Internal Medicine and Rheumatology.
Gantt diagram depicting a timeline of patients’ admissions in relationship with the three wards and the length of stay in each ward. Epidemic curve based on the number of K. pneumoniae isolated in the time frame of the study.Abbreviations: OAIT-Department of Anaesthesia and Intensive Care, NR-Department of Neurology with the Stroke Subdepartment, REU-Department of Internal Medicine and Rheumatology.

Fig. 2.

Dendrogram of XbaI-digested genomic DNA from carbapenemase-co-producing K. pneumoniae isolates, additionally presenting the results of PCRs for genes encoding carbapenemases and other β-lactamase. PFGE settings: similarity coefficient, Dice; optimization, 1%; tolerance, 1%; clustering method, UPGMA.
Dendrogram of XbaI-digested genomic DNA from carbapenemase-co-producing K. pneumoniae isolates, additionally presenting the results of PCRs for genes encoding carbapenemases and other β-lactamase. PFGE settings: similarity coefficient, Dice; optimization, 1%; tolerance, 1%; clustering method, UPGMA.

Antimicrobial resistance profiles of the studied K. pneumoniae isolates.

Patient ID/Isolate no.369656976/16976/21696824154/254287/2580411/2580813/25810675
Antibiotics:MIC (pg/ml)R/I/SMIC (pg/ml)R/I/SMIC (pg/ml)R/I/SMIC (pg/ml)R/I/SMIC (pg/ml)R/I/SMIC (pg/ml)R/I/SMIC (pg/ml)R/I/SMIC (pg/ml)R/I/SMIC (pg/ml)R/I/SMIC (pg/ml)R/I/SMIC (pg/ml)R/I/SMIC (pg/ml)R/I/SMIC (pg/ml)R/I/SMIC (pg/ml)R/I/SMIC (pg/ml)R/I/S
PenicillinsAmoxicillin/Clavulanic acid>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R
Ampicillin>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R
CephalosporinsCefaclor>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R
Cefuroxime>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R
Cefotaxime>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R
Cefotaxime/Cefotaxime + clavulanic acid>16/>1R>16/>1R>16/>1R>16/>1R>16/>1R>16/>1R>16/>1R>16/>1R>16/>1R>16/>1R>16/>1R>16/>1R>16/>1R>16/>1R>16/>1R
Ceftazidime>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R
Ceftazidime/Ceftazidime + clavulanic acid>34/>4R>34/>4R>34/>4R>34/>4R>34/>4R>34/>4R34/>4R>34/>4R>34/>4R>34/>4R>34/>4R>34/>4R>34/>4R>34/>4R>34/>4R
Cefepime>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R
CarbapenemsDoripenem>32R16R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R
Ertapenem>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R
Imipenem>32R>32R16R16R>32R>32R>32R>32R>12R4S4S8I>32R>32R>32R
Meropenem>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R
QuinoloneCiprofloxacin>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R
AminoglycosidesAmikacin4S8S32R32R8S12R6S4S8S8S8S8S12R6S6S
Gentamycin64R64R64R64R64R64R64R64R64R64R64R64R64R64R64R
Netylmycin128R4I64R64R128R32R16R16R12R16R16R16R32R16R16R
Tobramycin64R64R32R32R64R64R64R64R32R64R64R64R64R64R64R
OtherAztreonam>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R>256R
Colistin0.50S0.75S0.125S0.125S0.50S0.50S0.50S0.50S0.50S0.50S0.75S0.50S0.50S0.50S0.50S
Tetracycline32R128R8R8R32R32R32R8R>256R>256R>256R>256R8R8R128R
Tigecycline2R8R4R4R2R2R2R4R0.75R0.75R1.0R2R4R4R8R
Trimethoprim/Sulfamethoxazole>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R>32R
Fosfomycin>256R>256R>256R>256R>256R>256R>256R>256R>256R>256RR>256R>256R>256R>256R>256R

Demographic data and characteristics of the fourteen patients with K. pneumoniae co-producing KPC-2, OXA-48, VIM-1 and CTX-M-15 during the outbreak.

Patient ID/Isolate no.Age (years)/sexHospital ward(s)Date of isolationType of specimenStatus (type) of colonization/infectionDuration of hospitalization (days)Underlying conditionsAntimicrobial used prior to isolation of carbapenemase producer(s)Antimicrobial used as treatment for infectionsOutcome Alive/Dead
374/MOAIT08/03/2018Rectal swabColonization03/01-14/04/2018 (102 days)Abdominal Aortic Aneurysm (AAA)Ciprofloxacin + Gentamycin + ItraconazoleMetronidazoleDead
696560/FOAIT28/02/2018Rectal swabColonization08/02-01/04/2018 (53 days)Tuberculosis, Chronic Obstructive Pulmonary Disease (COPD)Colistin + VoriconazoleDead
6976/16976/245/MOAIT01/03/201812/03/2018Rectal swabBloodColonizationBacteremia21/02-29/03/2018 (37 days)Guillain-Barré Syndrome (GBS)Colistin + LinezolidAmpicillin/sulbactam + AmikacinAlive
167/FOAIT07/03/2018Rectal swabColonization02/03-29/06/2018 (112 days)COPD, diabetes, hypertensionCeftriaxone + LevofloxacinDead
6968 (index case)63/MNR28/02/2018Rectal swabColonization16/02-31/03/2018 (44 days)Hypertension, atherosclerosisCeftriaxone + MetronidazoleAlive
269/MNR07/03/2018Rectal swabColonization23/02-28/03/2018 (34 days)Post-stroke conditionsAlive
443/MNR08/03/2018Rectal swabColonization26/02-12/03/2018 (15 days)HypertensionCeftriaxone + MetronidazoleDead
154/2542861/MNR30/07/2018Rectal swabColonization04/07-06/08/2018 (34 days)StrokeDead
7/2580470/MNR04/08/2018Rectal swabColonization25/07-02/08/2018 (9 days)StrokeAmoxicillin/clavulanic acidAlive
11/2580850/FNR04/08/2018Rectal swabColonization23/07-03/08/2018 (12 days)StrokeAlive
13/2581077/MNR04/08/2018Rectal swabColonization22/07-09/08/2018 (19 days)Hypertension, ischemic heart diseaseAmoxicillin/clavulanic acidAlive
670/FREU09/03/2018Rectal swabColonization26/02-14/03/2018 (17 days)Diabetes, metastatic lung cancerAlive
778/FREU09/03/2018Rectal swabColonization27/02-16/03/2018(18 days)Rheumatoid Arthritis (RA), hemorrhagic diathesis, coronary disease, peptic ulcer disease, hypertension, atherosclerosis, goutImipenemVancomycinAlive
590/FREU08/03/2018Rectal swabColonization03.03-17.03.2018 (14 days)Atherosclerosis, acute arterial thrombosis of the lower extremityMeropenem + AmikacinAlive
eISSN:
2544-4646
Język:
Angielski
Częstotliwość wydawania:
4 razy w roku
Dziedziny czasopisma:
Life Sciences, Microbiology and Virology